UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 23, 2016
CELLDEX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | | 000-15006 | | 13-3191702 |
(State or Other Jurisdiction | | (Commission File Number) | | (IRS Employer |
of Incorporation) | | Identification No.) | | |
Perryville III Building, 53 Frontage Road, Suite 220, | | |
Hampton, New Jersey | | 08827 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (908) 200-7500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
Celldex Therapeutics, Inc. (the “Company”) hereby announces that the Company’s financial printer inadvertently submitted the Company’s annual report on Form 10-K for the year ended December 31, 2015 (the “10-K”) while preparing a test file. While the Company does not anticipate any substantive changes to this document, today’s version of the 10-K should be disregarded and, as previously disclosed, the Company intends to release fourth quarter and year-end 2015 financial results and file its 10-K on Thursday, February 25, 2016 before the U.S. financial markets open. The Company’s executives will host a conference call at 8:00 a.m. EST on February 25th to discuss 2015 financial and business results and to provide an update on key 2016 objectives.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CELLDEX THERAPEUTICS, INC. | |
| | |
| /s/ | | Anthony S. Marucci | |
| | Name: Anthony S. Marucci | |
| | Title: Chief Executive Officer | |
| | | | |
Dated: February 23, 2016
3
